Sight Sciences' fair access campaign aims for insured access to heat and expression therapy for meibomian gland dysfunction

Video

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, sat down with Optometry Times during the 2022 American Academy of Optometry meeting held in San Diego to share the impetus behind the company's fair access campaign.

Editor's note: This transcript has been edited for clarity.

Hi, my name is Jim Sluck, I'm Vice President of TearCare through Sight Sciences. I'm here to talk a little bit about our fair access campaign for insured access to heat and expression therapy.

The reality is there a lot of dry eye patients out there, and the vast majority have obstructive MGD [meibomian gland dysfunction]. We also know that only 5% of those patients are getting heat and expression therapy for this obstructive MGD.

The rationale for this low penetration of heat and expression utilization is that right now, this is a cash pay procedure. When if you think about care for dry eye--drugs, plugs, amniotic membranes--they're all covered by insurance in one shape, way or form. The fair access campaign is really driving for heat and expression, in this case through TearCare, to be an insured and reimbursed therapy that dry eye patients have access to.

We were telling this story to a number of ophthalmologists and optometrists across the country, and as we tell this story of access and fair reimbursement, they're so behind this that we couldn't tell the story one-on-one anymore, we had to start to campaign around it.

The first portion of the campaign that you'll see [is] our company folks talking to optometrists and ophthalmologists about why access is important.

The second portion will be peer-to-peer discussions with optometrists and ophthalmologists to their peer groups, talking about why access to care with a fair reimbursement is really important to overall patient care.

And lastly, it'll be patients talking to their payers about why their doctor should be able to use heat and expression to treat their dry eye, and why their doctors should be fairly reimbursed for that.

So that's the impetus behind the fair access campaign. Talk to us more about finding out more about the fair access campaign and TearCare at any point.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.